Immatics Raises €54 Million Series C To Fund Pivotal Therapeutic Cancer Vaccine Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
One of the largest European fundraisings this year, the round will help advance a potential therapeutic vaccine for kidney cancer through Phase III.
You may also be interested in...
Germany’s Immatics Biotech Raises $46M In Series D To Complete Cancer Vaccine Development
With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.
New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines
A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.
Wealthy Families Play A Growing Role in European Biotech Financing
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.